PUBLISHER: Polaris Market Research | PRODUCT CODE: 1586360
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1586360
Europe SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication, Drug, Distribution Channel, and Country (Germany, France, UK, Italy, Spain, Netherlands, Russia, and Rest of Europe) - Market Forecast, 2024-2032
The Europe SGLT2 inhibitors market size is expected to reach USD 7,629.79 million by 2032, according to a new study by Polaris Market Research. The report "Europe SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD) Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country; Market Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
SGLT2 inhibitors are known for their ability to lower blood glucose levels by inhibiting the reabsorption of glucose in the kidneys, leading to its excretion in the urine. This mechanism aids in managing blood sugar levels and contributes to weight loss as the excreted glucose represents a loss of calories. Additionally, SGLT2 inhibitors have demonstrated the ability to reduce cardiovascular risks, which is particularly significant for diabetes patients who are at a higher risk for heart disease. These benefits of SGLT2 inhibitors make them an appealing treatment option for patients and healthcare providers, making them preferable over other diabetes medications.
European governments are pivotal in supporting diabetes care through policies and initiatives such as promoting early diagnosis through regular screenings, encouraging preventive measures such as lifestyle modifications, and subsidizing medication access to enhance affordability and accessibility for the population. Such government support ensures that a larger segment of the population can benefit from advanced treatments such as SGLT2 inhibitors.
The well-established healthcare systems in Europe play a significant role in driving the growth of the SGLT2 inhibitors market in the region. The robust healthcare infrastructure in the region ensures that patients have access to advanced medical treatments and technologies, facilitating widespread adoption and distribution of medications, including SGLT2 inhibitors.
Europe is witnessing rising public health campaigns and education initiatives to raise awareness about diabetes, its complications, and the importance of early diagnosis and management. These initiatives educate the public about the benefits of effective diabetes treatments, including SGLT2 inhibitors, thereby encouraging more people to seek timely medical advice and treatment. The heightened awareness has led to a significant increase in the diagnosis of diabetes and the subsequent use of SGLT2 inhibitors, thereby boosting their market share.
Europe SGLT2 Inhibitors Market Report Highlights
In terms of drug, the Jardiance (Empagliflozin) segment accounted for the largest revenue share in the Europe SGLT2 inhibitors market in 2023. Major health organizations and regulatory bodies such as the European Medicines Agency (EMA) and the American Diabetes Association (ADA) recommend the use of Jardiance for the treatment of type 2 diabetes.
The type 2 diabetes segment, by indication, is expected to register the highest CAGR during the forecast period. Governments and healthcare organizations in Europe are implementing policies and initiatives such as promoting early diagnosis through regular screenings, funding diabetes education programs, and subsidizing the cost of medications. Such measures increase accessibility and affordability of diabetes treatments, boosting market growth.
In 2023, the UK accounted for the largest share of the Europe SGLT2 inhibitors market. The country hosts numerous prominent pharmaceutical companies and research institutions committed to advancing and commercializing treatments for diabetes.
AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; and Pfizer Inc. are among the key players in Europe.
Polaris Market Research has segmented the Europe SGLT2 inhibitors market report on the basis of indication, drug, distribution channel, and country:
By Indication Outlook (Revenue - USD million, 2019-2032)
- Cardiovascular
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes
- Others
By Drug Outlook (Revenue - USD million, 2019-2032)
- Farxiga (Dapagliflozin)
- Inpefa (Sotagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other Europe SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue - USD million, 2019-2032)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Country Outlook (Revenue - USD million, 2019-2032)
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Europe SGLT2 Inhibitors Market Insights
- 4.1. Europe SGLT2 Inhibitors Market - Market Snapshot
- 4.2. Europe SGLT2 Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Geriatric Population in Europe Drives Market Growth
- 4.2.1.2. Increasing Government Initiatives Drive Market Outlook
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Alternative Treatment Options
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Europe SGLT2 Inhibitors Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Europe SGLT2 Inhibitors Market, by Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 5.3. Cardiovascular
- 5.3.1. Europe SGLT2 Inhibitors Market, by Cardiovascular, by Country, 2019-2032 (USD million)
- 5.4. Chronic Kidney Disease (CKD)
- 5.4.1. Europe SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Country, 2019-2032 (USD million)
- 5.5. Type 2 Diabetes
- 5.5.1. Europe SGLT2 Inhibitors Market, by Type 2 Diabetes, by Country, 2019-2032 (USD million)
- 5.6. Others
- 5.6.1. Europe SGLT2 Inhibitors Market, by Others, by Country, 2019-2032 (USD million)
6. Europe SGLT2 Inhibitors Market, by Drug
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 6.3. Farxiga (Dapagliflozin)
- 6.3.1. Europe SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Country, 2019-2032 (USD million)
- 6.4. Inpefa (Sotagliflozin)
- 6.4.1. Europe SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Country, 2019-2032 (USD million)
- 6.5. Invokana (Canagliflozin)
- 6.5.1. Europe SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Country, 2019-2032 (USD million)
- 6.6. Jardiance (Empagliflozin)
- 6.6.1. Europe SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Country, 2019-2032 (USD million)
- 6.7. Qtern (Dapagliflozin/Saxagliptin)
- 6.7.1. Europe SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Country, 2019-2032 (USD million)
- 6.8. Other Europe SGLT2 Inhibitors
- 6.8.1. Europe SGLT2 Inhibitors Market, by Other Europe SGLT2 Inhibitors, by Country, 2019-2032 (USD million)
7. Europe SGLT2 Inhibitors Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 7.3. Hospital Pharmacies
- 7.3.1. Europe SGLT2 Inhibitors Market, by Hospital Pharmacies, by Country, 2019-2032 (USD million)
- 7.4. Online Pharmacies
- 7.4.1. Europe SGLT2 Inhibitors Market, by Online Pharmacies, by Country, 2019-2032 (USD million)
- 7.5. Retail Pharmacies
- 7.5.1. Europe SGLT2 Inhibitors Market, by Retail Pharmacies, by Country, 2019-2032 (USD million)
8. Europe SGLT2 Inhibitors Market, by Country
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Europe SGLT2 Inhibitors Market Assessment, By Country, 2019-2032 (USD million)
- 8.3. Europe SGLT2 Inhibitors Market
- 8.3.1. Europe: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.2. Europe: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.3. Europe: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.4. Europe SGLT2 Inhibitors Market - UK
- 8.3.4.1. UK: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.4.2. UK: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.4.3. UK: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.5. Europe SGLT2 Inhibitors Market - France
- 8.3.5.1. France: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.5.2. France: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.5.3. France: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.6. Europe SGLT2 Inhibitors Market - Germany
- 8.3.6.1. Germany: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.6.2. Germany: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.6.3. Germany: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.7. Europe SGLT2 Inhibitors Market - Italy
- 8.3.7.1. Italy: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.7.2. Italy: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.7.3. Italy: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.8. Europe SGLT2 Inhibitors Market - Spain
- 8.3.8.1. Spain: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.8.2. Spain: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.8.3. Spain: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.9. Europe SGLT2 Inhibitors Market - Netherlands
- 8.3.9.1. Netherlands: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.9.2. Netherlands: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.9.3. Netherlands: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.10. Europe SGLT2 Inhibitors Market - Russia
- 8.3.10.1. Russia: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.10.2. Russia: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.10.3. Russia: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- 8.3.11. Europe SGLT2 Inhibitors Market - Rest of Europe
- 8.3.11.1. Rest of Europe: Europe SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- 8.3.11.2. Rest of Europe: Europe SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- 8.3.11.3. Rest of Europe: Europe SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Boehringer Ingelheim International GmbH
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Glenmark Pharmaceuticals Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Lexicon Pharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Novo Nordisk
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Sanofi
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Pfizer Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
List of Tables:
- Table 1 Europe: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 2 Europe: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 3 Europe: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 4 UK: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 5 UK: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 6 UK: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 7 France: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 8 France: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 9 France: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 10 Germany: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 11 Germany: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 12 Germany: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 13 Italy: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 14 Italy: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 15 Italy: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 16 Spain: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 17 Spain: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 18 Spain: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 19 Netherlands: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 20 Netherlands: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 21 Netherlands: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 22 Russia: GLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 23 Russia: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 24 Russia: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
- Table 25 Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2019-2032 (USD million)
- Table 26 Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2019-2032 (USD million)
- Table 27 Rest of Europe: SGLT2 Inhibitors Market, by Distribution Channel, 2019-2032 (USD million)
List of Figures:
- Figure 1. Europe SGLT2 Inhibitors Market, 2019-2032 (USD million)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Price
- Figure 4. Market by Country
- Figure 5. Porter's Five Forces
- Figure 6. Market by Indication
- Figure 7. Europe SGLT2 Inhibitors Market, by Indication, 2023 & 2032 (USD million)
- Figure 8. Market by Drug
- Figure 9. Europe SGLT2 Inhibitors Market, by Drug, 2023 & 2032 (USD million)
- Figure 10. Market by Distribution Channel
- Figure 11. Europe SGLT2 Inhibitors Market, by Distribution Channel, 2023 & 2032 (USD million)
